|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||3.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.
OTCQX:EMHTF) ("Emerald" or the “Company”) closed today its prospectus sale (the “Offering”) to a single Canadian institutional accredited investor (the “Investor”) announced on December 3, 2018. Pursuant to the Offering, the Company has issued 4,000,000 common shares of the Company (the "Common Shares") at a price per Common Share of $2.70, for gross proceeds of $10.8 million. The Investor has an option (the “Option”) to acquire up to a maximum of 1,555,555 additional Common Shares at a price per Common Share of $2.70 for a period of ten business days from the closing date.
This has been a big year for production and product line expansion, but it doesn't necessarily make this marijuana stock a buy.
OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.
Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.
On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs, in which the latter will supply up to 900 kilograms of cannabis extract to Canopy Growth and its subsidiaries for sale. Initially, Canopy Growth committed to a minimum purchase of 450 kilograms, which could later be extended to another 450 kilograms.
OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the three and nine months ended September 30, 2018. “During the third quarter, we’ve fulfilled our initial supply scheduling, product, and volume commitments to our provincial cannabis distribution customers to participate in the adult-use cannabis market – demonstrating our ability to provide consistent and increasing contracted shipments of Emerald product,” said Avtar Dhillon, MD, President of Emerald Health Therapeutics.
OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Emerald Health Therapeutics, Inc. (EMHTF), a licensed Canadian producer of cannabis. From an industry perspective, the recent legalization of cannabis sales for adult recreational use in Canada was a watershed moment for the entire industry and the Company.
Supreme Cannabis (SPRWF) is among the worst performers in the sector so far this year. The company’s stock closed nearly 39% lower YTD, which is similar to Emerald Health (EMHTF), which declined by nearly 43% so far this year as of November 19. Let’s look at how the analysts’ price targets and recommendations have changed in November.
VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.
OTCQX:EMHTF) is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.
MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (LABS.V) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. “This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.
CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Marijuana stocks have seen a surge of attention this year. This event has been well received by the public markets as many marijuana stocks have positively reacted to this news. Sessions, who has been a staunch adversary of the legalization of cannabis, took a very conservative approach when broaching the subject.
HENDERSON, NV / ACCESSWIRE / November 8, 2018 / A major stem cell report was released today. Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may ...
OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.
HENDERSON, NV / ACCESSWIRE / October 23, 2018 / We have several stocks on our radar for a big week. One that is jumping off the screen CleanSpark, Inc. (CLSK). If you look at their recent filings you'll ...
OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use. The products provide more precise and consistent delivery, dosage, and formulations.
OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. “Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald.
MediPharm Labs Corp. ("MediPharm") (LABS.V) is pleased to announce that it has entered into a Cannabis Concentrate Program Agreement (the "Agreement") with Emerald Health Therapeutics Inc. ("Emerald") (TSXV: EMH - OTCQX:EMHTF). Pursuant to the Agreement, signed on October 5, 2018, Emerald will provide MediPharm with dried cannabis to create premium quality cannabis oil (the "Program"). The Agreement enables Emerald to provide pharmaceutical grade cannabis concentrate products produced by MediPharm to its large base of registered patients, as well as provide adult-use recreational consumers with premium quality cannabis concentrates commencing October 17, 2018.
OTCQX:EMHTF) (“Emerald”) announced today that Northern Vine Canada Inc. (Northern Vine), a wholly owned subsidiary of Emerald, successfully completed the export of cannabis oil to the United States on May 25 pursuant to an import permit from the federal U.S. Drug Enforcement Agency (DEA). The cannabidiol (CBD)-containing cannabis oil is expected to be used by a US biopharmaceutical company to develop its proprietary cannabinoid technology for medical research and development and for its manufacturing process for future clinical trials.
VICTORIA, British Columbia, Oct. 09, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Northern Vine Canada Inc..
OTCQX:EMHTF) (“Emerald”) has entered into a research agreement with VivaCell Biotechnologies Spain S.L.U. (“VivaCell”). VivaCell is an institute focused on cannabis research, which will provide its cannabis-industry-leading contract research organization (CRO) services to Emerald to elucidate the mechanism of action of proprietary formulations and dosage forms that Emerald is developing. This collaboration has the potential to strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery, dosage, and formulations.